Rare EU Fast-Track Nod For Sanofi Genzyme's Olipudase Alfa

Product Is One Of Few To Secure Accelerated Assessment In Recent Months

Only three planned marketing authorization applications are known to have been granted accelerated assessment status by the European Medicines Agency between July and October this year. 

Winners or Losers - Traffic sign with two options
More EU fast-track requests get rejected than accepted • Source: Alamy

The EU marketing authorization application (MAA) for Sanofi Genzyme's olipudase alfa will be reviewed under the European Medicines Agency's accelerated assessment mechanism when the company files for approval.

Olipudase alfa is a potential therapy for the long-term treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD),...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography